Literature DB >> 15491387

Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy.

Hiroshi Tanaka1, Koichi Suzuki, Tohru Nakahata, Koji Tsugawa, Yuki Konno, Kazushi Tsuruga, Etsuro Ito, Shinobu Waga.   

Abstract

BACKGROUND: It has been reported that combined therapy of angiotensin converting enzyme inhibitor and angiotensin receptor blocker significantly decreases proteinuria in immunoglobulin A (IgA) nephropathy. However, histologic alterations following the therapy have not been reported.
METHODS: A total of nine Japanese children with severe proteinuric IgA nephropathy who received a prompt immunosuppressive therapy were enrolled the study, four of whom received a combined therapy of angiotensin converting enzyme inhibitor, enalapril and angiotensin receptor blocker, losartan (Group A), while the remaining five did not (Group B). All underwent renal biopsy before and approximately 12 months after the first renal biopsy.
RESULTS: At presentation, urine protein excretion and the histologic indices of mean activity index, mean chronicity index and tubulointerstitial scores did not show a statistical difference between the two groups: Group A (2.6 +/- 0.6 g/day; mean activity index, 5.0 +/- 1.0; mean chronicity index, 5.0 +/- 1.0; tubulointerstitial scores, 4.3 +/- 1.0) and Group B (2.2 +/- 0.6 g/day; mean activity index, 4.8 +/- 0.8; mean chronicity index, 4.8 +/- 1.3; tubulointerstitial scores, 3.6 +/- 0.5, respectively). All had normal blood pressure and renal function. Urine protein excretion and the activity index decreased at the second renal biopsy, while the chronicity index and the tubulointerstitial scores slightly increased or remained unchanged. In comparison with Group B, a significant suppression in increasing the chronicity index and the tubulointerstitial scores obtained at the second renal biopsy were observed in Group A [Group A: 4.3 +/- 1.2 and 3.0 +/- 0.0, respectively, vs Group B: 6.0 +/- 0.7 and 4.4 +/- 0.9, respectively (P < 0.05)]. One patient in Group B developed chronic renal insufficiency thereafter.
CONCLUSIONS: Although only a small number of patients were examined, these clinical findings suggest that a combined therapy of enalapril and losartan may attenuate histologic progression in at least a proportion of patients with severe proteinuric IgA nephropathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15491387     DOI: 10.1111/j.1442-200x.2004.01955.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  14 in total

Review 1.  Future pharmacologic agents for treatment of heart failure in children.

Authors:  Brady S Moffett; Anthony C Chang
Journal:  Pediatr Cardiol       Date:  2006-08-23       Impact factor: 1.655

Review 2.  Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; A Boldt; U Sack; J Fahnert
Journal:  Clin Exp Immunol       Date:  2016-09-08       Impact factor: 4.330

3.  Angiotensin blockade in children with chronic glomerulonephritis and heavy proteinuria.

Authors:  Lavjay Butani
Journal:  Pediatr Nephrol       Date:  2005-08-16       Impact factor: 3.714

Review 4.  Treatment of IgA nephropathy and Henoch-Schönlein nephritis.

Authors:  Jürgen Floege; John Feehally
Journal:  Nat Rev Nephrol       Date:  2013-04-02       Impact factor: 28.314

5.  Changes in urinary angiotensinogen posttreatment in pediatric IgA nephropathy patients.

Authors:  Maki Urushihara; Takashi Nagai; Yukiko Kinoshita; Sato Nishiyama; Kenichi Suga; Natsuko Ozaki; Ariunbold Jamba; Shuji Kondo; Hiroyuki Kobori; Shoji Kagami
Journal:  Pediatr Nephrol       Date:  2014-12-20       Impact factor: 3.714

6.  Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors.

Authors:  Mieczysław Litwin; Ryszard Grenda; Joanna Sladowska; Jolanta Antoniewicz
Journal:  Pediatr Nephrol       Date:  2006-08-15       Impact factor: 3.714

Review 7.  Educational paper: Progression in chronic kidney disease and prevention strategies.

Authors:  Betti Schaefer; Elke Wühl
Journal:  Eur J Pediatr       Date:  2012-09-12       Impact factor: 3.183

8.  Treatment of severe Henoch-Schönlein and immunoglobulin A nephritis. A single center experience.

Authors:  Stella Edström Halling; Magnus P Söderberg; Ulla B Berg
Journal:  Pediatr Nephrol       Date:  2008-10-18       Impact factor: 3.714

Review 9.  Non-immunosuppressive therapies for childhood IgA nephropathy.

Authors:  Yuko Shima; Koichi Nakanishi; Norishige Yoshikawa
Journal:  Pediatr Nephrol       Date:  2021-02-16       Impact factor: 3.714

10.  Comparative efficacy of different renin angiotensin system blockade therapies in patients with IgA nephropathy: a Bayesian network meta-analysis of 17 RCTs.

Authors:  Zhihao Huo; Huizhen Ye; Peiyi Ye; Guanqing Xiao; Zhe Zhang; Yaozhong Kong
Journal:  PeerJ       Date:  2021-07-06       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.